Licensing
🌏 NMPANMPA news and analysis for pharmaceutical BD, investment, and market access
Unlock global pharma market opportunities. Get expert insights on drug licensing deals, IP strategies, and M&A trends for strategic BD.
Showing 1–7 of 7 articles
Quick answer
NovaPharmaNews Licensing hub for NMPA covers 7 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
Fosun Pharma and AriBio Forge Alzheimer's Option Agreement: Deal Intelligence
Big Pharma's China Oncology Trials: Navigating a Landscape of Reduced Scrutiny
Kissei Pharmaceutical Halts Tavneos Use Amid Deaths
Injectable Drug Delivery Market Set for Significant Growth: Insights for Pharma Stakeholders
Minghui and Qilu Pharmaceutical Unveil Promising MHB088C Data in mCRPC at ASCO 2026
BeOne Medicines' HERIZON-GEA Phase 3 Data in NEJM: A Deep Dive for Pharma BD and Investors
Biogen Acquires Felzartamab Rights from TJ Biopharma for Greater China Market
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.